Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

17 Jul 2013 07:00

RNS Number : 4730J
Imperial Innovations Group plc
17 July 2013
 



17 July 2013

 

Imperial Innovations Group plc

 

Board change

 

Imperial Innovations Group plc (AIM: IVO, "Innovations" or "the Group"), a leading technology commercialisation and investment group, announces that Susan Searle has stepped down as Chief Executive Officer. Russ Cummings, Chief Investment Officer and a director since the Group's flotation in 2006, has become Chief Executive Officer with immediate effect.

 

Russ Cummings previously worked at Scottish Equity Partners where as director in the Information Technology Group he was responsible for investment in high growth technology companies. Previously, Russ worked at 3i Group for 16 years including being a director in their UK Technology Group and at Rolls-Royce Motors as a development engineer. Russ has a BSc in Mechanical Engineering from Imperial College London.

 

Martin Knight, Chairman of the Group, said:

 

"On behalf of the Board and the Group as whole, I would like to thank Susan for her considerable contribution over the last nearly 20 years, 11 of which have been as Chief Executive Officer. She led our Admission to AIM in 2006 and two subsequent equity fund raisings.

 

"During her tenure, she transformed the Group from an operational division of Imperial College London, as its technology transfer office, to a major independent venture capital and technology licensing business.

 

"Thanks to her efforts, Innovations now has a stable platform from which it can deliver its long-term ventures and licensing business objectives. We all wish her well for the future.

 

"Russ has an excellent track record in early stage investing and high growth companies spanning both the healthcare and technology sectors. He was recruited in 2006 as CIO to build the investment team. He has played a significant role on the boards of two of our flagship investments, Nexeon and Circassia.

 

"Russ has been a key part of the management team and is ideally suited to lead Innovations in the next phase of its development."

 

Susan Searle said:

 

"I feel privileged for over 11 years to have led the management team at Innovations in building such a great company that it is today. But I have decided that now is the right time for me to step down. The timing of this decision is both good for me and for the business and enables my successor to make a very smooth transition to his role.

 

"The business is currently in a strong position and has recently concluded an additional £30m of funding from the European Investment Bank, enabling the Group to grow its investments still further. Innovations has some very exciting companies in its portfolio which we have worked hard to support and are based on world class science, with high quality management and are backed by strong investment syndicates.

 

"The Innovations story is set to continue and thrive in the long term and I wish it and the team every success.

 

"I now plan to go plural and to join a number of both larger and smaller public and private companies across a range of sectors, including biotech, engineering and technology, and investment in the UK and internationally."

 

Enquiries:

 

Imperial Innovations Group Plc

020 7594 6506

Martin Knight, Chairman

College Hill

020 7457 2020

Adrian Duffield/Tim Watson/Rozi Morris

J.P. Morgan Cazenove

020 7742 4000

Michael Wentworth Stanley/Alec Pratt

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGGUCCMUPWGQQ
Date   Source Headline
28th Jul 20157:01 amRNS£1 million seed investment in Inflowmatix
27th Jul 20157:00 amRNS£3.0 million investment in Concirrus
23rd Jul 20151:35 pmRNSDirectorate Change
14th Jul 20157:00 amRNSFurther £50m loan facility from EIB
2nd Jul 20157:00 amRNS£4.0m funding round in Impression Technologies
1st Jul 20157:00 amRNSFirst subject enrolled in Veryan Medical's study
30th Jun 20157:00 amRNSLeads £3 million investment in Abingdon Health
8th Jun 20151:18 pmRNSDirectorate Change
3rd Jun 20157:00 amRNSInnovations leads £6m funding round in Auspherix
29th May 20157:00 amRNSAppointment of Executive Chairman at Kesios
27th May 20154:05 pmRNSHolding(s) in Company
26th May 20157:01 amRNSDivests its shares of Epigeum
19th May 20157:00 amRNS£25m Series C funding round in PsiOxus
14th May 20157:00 amRNSTopiVert starts Phase I Clinical Trial
30th Apr 20153:48 pmRNSDirector's share purchase
27th Apr 20157:00 amRNSAutifony Therapeutics recruits first trial patient
15th Apr 20157:00 amRNSInnovations leads £5.9m funding round in Yoyo
27th Mar 20157:00 amRNSHalf Yearly Report
24th Mar 20154:40 pmRNSSecond Price Monitoring Extn
24th Mar 20154:35 pmRNSPrice Monitoring Extension
18th Mar 20157:00 amRNSCell Medica granted Orphan Drug designation
13th Mar 201510:07 amRNSEdison publishes research on Imperial Innovations
27th Feb 201511:48 amRNSNotice of Results
19th Feb 20157:00 amRNSCell Medica to commence cell therapy manufacture
14th Jan 201512:13 pmRNS£18 million Series B funding round in Veryan
18th Dec 20147:00 amRNSImperial named UK's top research university
16th Dec 201411:39 amRNSResult of AGM
9th Dec 20142:55 pmRNSGrant of options under SAYE Scheme
26th Nov 20143:41 pmRNSGrant of share options
25th Nov 201410:45 amRNSReplacement Director's share purchase
25th Nov 20147:00 amRNS£50 million Series B funding round in Cell Medica
24th Nov 20144:20 pmRNSDirector's share sale
12th Nov 20147:00 amRNSPosting of Annual Report and Notice of AGM
24th Oct 20147:00 amRNSDirectorate Changes
15th Oct 20147:00 amRNSFinal Results
8th Oct 20147:00 amRNSInnovations invests £1.85m in Kesios Therapeutics
5th Sep 20141:55 pmRNSNotice of Results
13th Aug 201412:43 pmRNSDirector's share sale
15th Jul 20142:08 pmRNSDirectorate Change
7th Jul 20147:14 amRNSPortfolio company Abzena announces offer price
4th Jul 20143:36 pmRNSHolding(s) in Company
23rd Jun 20143:15 pmRNSResults of Placing
23rd Jun 20147:00 amRNSPlacing to raise £150 million
19th Jun 201412:45 pmRNSResult of General Meeting
16th Jun 20147:09 amRNSPortfolio company announces intention to float
12th Jun 20147:00 amRNSImperial Innovations invests £1.5m in Cortexica
10th Jun 20147:00 amRNS£3 million funding round for Featurespace
4th Jun 20147:00 amRNSAutifony receives funding for Phase II trial
2nd Jun 20147:00 amRNSAppointment of non-executive directors
2nd Jun 20147:00 amRNSProposed Placing to raise up to £150 million

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.